Results 181 to 190 of about 7,461 (205)

Comprehensive pharmacogenomics profiling of the Serbian population. [PDF]

open access: yesFront Pharmacol
Jelovac M   +6 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Genetic Variation in VKORC1 and Risk for Osteoporosis

Archives of Medical Research, 2021
The vitamin K epoxide reductase complex subunit 1 (VKORC1) plays an important role in bone development and bone metabolism by influencing the vitamin K cycle. The aim of this study was to investigate the association between VKORC1 gene polymorphisms and bone mineral density and the risk of osteoporosis.We determined VKORC1 gene polymorphisms (rs9923231
Jin, He   +5 more
openaire   +2 more sources

The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations

Journal of Applied Genetics, 2014
The vitamin K epoxide reductase (VKORC1) is a key enzyme in the vitamin K cycle impacting various biological processes. VKORC1 genetic variability has been extensively studied in the context of warfarin pharmacogenetics revealing different distributions of VKORC1 haplotypes in various populations.
Sophia, Sominsky   +8 more
openaire   +2 more sources

VKORC1 and the Vitamin K Cycle

2008
Vitamin K epoxide, a product of gamma-carboxylation, must be rapidly recycled to its reduced form before it can be reused. The set of sequential reactions that guarantees vitamin K recycling is known as the vitamin K cycle. This review is focused on biochemical and genetic aspects of a recently characterized key enzyme of the cycle named vitamin K ...
Andrea A, Garcia, Pieter H, Reitsma
openaire   +2 more sources

VKORC1 Polymorphisms in Amerindian Populations of Brazil

Pharmacogenomics, 2008
Noncoding polymorphisms in the VKORC1 gene associate with variation of interindividual dosing requirements of warfarin and other coumarin anticoagulants. The frequency of VKORC1 polymorphisms displays distinct interpopulation differences. Here, we report the distribution of the VKORC1 3673G>A, 5808T>G, 6853G>C and 9041G>A SNPs in three endogamous ...
Jamila A, Perini   +3 more
openaire   +2 more sources

VKORC1 and CYP2C9 genotype distribution in Asian countries

Thrombosis Research, 2014
Warfarin is the most widely used anticoagulant all over the world for prevention and treatment of different thrombotic conditions. Polymorphisms in two genes i.e. CYP2C9 (Cytochrome P450 2C9) and VKORC1 (Vitamin K epoxide reductase complex subunit 1) play a major role in warfarin dose variation and its related adverse effects.
Tejasvita, Gaikwad   +2 more
openaire   +2 more sources

VKORC1: the little big protein

Blood, 2005
Comment on Sun et al, page [3811][1] VKORC1, the recently identified protein of the vitamin K cycle, catalyzes vitamin K epoxide to vitamin K and further to vitamin K hydroquinone, thus representing the rate-limiting enzyme for the carboxylation of vitamin K–dependent proteins.
openaire   +1 more source

Association between VKORC1 gene polymorphism and warfarin dose requirement and frequency of VKORC1 gene polymorphism in patients from Kerman province

The Pharmacogenomics Journal, 2020
Warfarin is an anticoagulant prescribed in the treatment and prevention of thrombosis. Variation in dose requirements is different for everyone, and genetic factors have an effect on dose variation. Polymorphism of vitamin K epoxide reductase complex 1 (VKORC1) gene is identified as the main genetic factor involved in warfarin dosage requirement ...
Mohammad Javad Soltani Banavandi   +1 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy